Well I found this the most informative of the three newsletters they have released.
When speaking of the companies that have been provided samples:
"The approach to testing varies from company to company. Some are focusing on a single major application for thetechnology, whilst others are interested in broader, more general screening as they look for the best opportunity to takethese new molecules to market. In all cases these companies are making significant investment into the testing of ourcompounds, and importantly, we will have access to the data produced."
And he said they are conducting the toxicology studies that are needed.
It's probably good that they are doing a conference call and taking questions. They didn't need to do that. Hopefully this will clarify things for shareholders.
BGT Price at posting:
9.9¢ Sentiment: Hold Disclosure: Held
